How do you choose an insurance broker for a life sciences company?

For a life sciences company, the broker decision matters more than for a typical small business, because the exposures are specialized, the contracts are demanding, and a single coverage gap discovered at MSA-review or claim time can be existential. The right broker is a specialist who places this risk repeatedly, not a generalist adding you to a book of restaurants and contractors.

The evaluation comes down to five questions: Can they access the right markets? Can they read your contracts? Will they fight a claim? Can they build a program that scales? And do they actually understand your sub-vertical?

The single biggest differentiator is which markets a broker can actually reach. Life-sciences risk - products liability for a contract manufacturer, D&O for a clinical-stage biotech, professional liability for a CRO, recall for a 503B - is written by a relatively small set of specialty carriers with the appetite and forms to do it well. Generic commercial markets will often quote the same risk, but with forms that exclude or under-cover the exposures that matter.

Ask a prospective broker which markets they would approach for your specific risk and why. A specialist names markets and explains the trade-offs in their forms; a generalist talks in generic terms about "shopping it around." The difference shows up later as either a clean claim payment or a coverage dispute.

Life-sciences companies live and die by their contracts - sponsor MSAs, GPO supplier agreements, PBM credentialing packets, hospital purchase contracts, clinical trial agreements, 503B outsourcing agreements. Each contains an insurance schedule itemizing required limits, endorsements (additional insured for products/completed operations, primary and non-contributory, waiver of subrogation), and documentation.

A specialist broker reads those schedules and tells you, before you sign, whether your program complies and exactly what has to change if it does not. A generalist hands you a certificate of insurance and leaves you to discover the gap when the counterparty's credentialing platform rejects it line by line. The ability to turn a contract's insurance section into a clear "you comply / here is the gap" answer is the most practical test of specialization.

A policy is only as good as the claim it pays. Ask how the broker handles claims: do they advocate with the carrier on your behalf, or hand you a claims phone number? For specialized exposures - a product recall, a trial-subject injury, a D&O demand - the broker's willingness and ability to push a carrier toward coverage is worth more than a small premium difference.

Reference checks matter here. Ask a prospective broker to connect you with a client who has had a claim in your sub-vertical, and ask that client how the broker behaved when money was actually on the line.

A small life-sciences company is a moving target: it raises capital (triggering or re-sizing D&O), starts trials (triggering clinical trial liability), signs its first hospital or sponsor contract (dictating products limits and umbrella), and may transition regulatory status (a 503A becoming a 503B rebuilds the entire program). A good broker designs a program that anticipates the next stage rather than patching the current one.

Ask how they would expect your program to change over the next 24 months given your roadmap. A specialist describes the triggers and the sequence; a generalist quotes today's exposure and revisits it at renewal, which is how companies end up non-compliant the moment a new contract or round closes.

Life sciences is not one risk - a biotech, a CRO, a CDMO, a medical device maker, a diagnostic lab, and a compounding pharmacy have materially different exposures and contract patterns. A broker fluent in your specific sub-vertical knows that a CDMO needs products as the primary line with blanket additional-insured-for-products, that a CRO's core exposure is professional liability and trial-subject injury, that a 503B needs recall and cGMP-aware property, and that a clinical-stage biotech's first real exposure is D&O.

You can test this in one conversation. A specialist asks about your contracts, your stage, your data, and your regulatory status before quoting anything. A generalist asks for your revenue and employee count and produces a generic business-owner's policy. The first questions a broker asks tell you most of what you need to know.

An independent broker who can access multiple specialty markets generally serves a life-sciences company better than a captive agent tied to a single carrier's appetite, because no single carrier writes every life-sciences line well. The value is in matching each line to the market that writes it best and in having leverage at renewal.